Stone Warren 4

What Happened Warren Stone, President & Chief Operating Officer of Neogenomics (NEO), received compensation awards on March 1, 2026: 253,378 stock options and 152,594 restricted stock units (RSUs). The awards are compensation grants (transaction code A), not open‑market purchases or sales. Together they cover up to 405,972 potential shares if the RSUs vest and the options are exercised. The Form 4 was filed on March 3, 2026.

Key Details

• Transaction date: March 1, 2026; Form 4 filed March 3, 2026 (within the standard two-business-day window).
• Awards: 253,378 stock options (derivative) and 152,594 restricted stock units (derivative).
• Vesting: Both grants vest ratably over the first three anniversary dates of the grant (footnotes F2 and F3).
• Option pricing: The options were granted as premium‑price options (footnote indicates exercise price was set at 110% of a recent closing price — per filing methodology).
• Shares after transaction: Not specified in the provided excerpt of the filing.
• Other notable footnotes: Prior grants and modified vesting schedules related to Mr. Stone’s promotion to President & COO (see footnotes F16–F20). Footnote F4 notes that once vested, the shares of common stock are not subject to expiration.

Context

• These are compensation awards (routine for executives) and do not represent a market purchase or sale. RSUs convert to shares only as they vest; options create the right to buy shares at a set exercise price and require exercise to become shares.
• Premium‑priced options (exercise price above recent market) are intended to align incentives with stock price growth.
• This filing reports new grants rather than insider buying/selling; such awards are common as part of executive pay and don’t, by themselves, signal an immediate market action.